Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,153Revenue (TTM) $M757Net Margin (%)14.3Altman Z-Score14.7
Enterprise Value $M1,936EPS (TTM) $1.5Operating Margin %22.1Piotroski F-Score8
P/E(ttm)20.7Beneish M-Score-2.8Pre-tax Margin (%)22.1Higher ROA y-yY
Price/Book2.810-y EBITDA Growth Rate %--Quick Ratio5.3Cash flow > EarningsY
Price/Sales3.05-y EBITDA Growth Rate %13.4Current Ratio5.6Lower Leverage y-yY
Price/Free Cash Flow14.5y-y EBITDA Growth Rate %14.7ROA % (ttm)13.3Higher Current Ratio y-yY
Dividend Yield %--PEG1.5ROE % (ttm)15.2Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M70.3ROIC % (ttm)20.1Gross Margin Increase y-yN

Gurus Latest Trades with MYGN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
MYGNJoel Greenblatt 2016-03-31 Add$34.12 - $43.16
($37.75)
$ 30.62-19%Add 2.63%201,527
MYGNKen Fisher 2016-03-31 Add$34.12 - $43.16
($37.75)
$ 30.62-19%Add 0.01%89,783
MYGNJoel Greenblatt 2015-12-31 Buy 0.09%$37.77 - $46.16
($42.36)
$ 30.62-28%New holding196,364
MYGNKen Fisher 2015-09-30 Add$30.94 - $41.39
($35.43)
$ 30.62-14%Add 1.96%89,775
MYGNJoel Greenblatt 2015-03-31 Sold Out -0.16%$32.63 - $39.49
($35.79)
$ 30.62-14%Sold Out0
MYGNMario Gabelli 2015-03-31 Buy $32.63 - $39.49
($35.79)
$ 30.62-14%New holding25,000
MYGNKen Fisher 2015-03-31 Reduce$32.63 - $39.49
($35.79)
$ 30.62-14%Reduce -0.32%88,050
MYGNJoel Greenblatt 2014-12-31 Reduce-0.11%$32.01 - $39.49
($35.44)
$ 30.62-14%Reduce -34.58%568,865
MYGNKen Fisher 2014-12-31 Buy 0.01%$32.01 - $39.48
($35.39)
$ 30.62-13%New holding88,333
MYGNJoel Greenblatt 2014-09-30 Reduce-0.12%$35.44 - $40.41
($37.28)
$ 30.62-18%Reduce -22.18%869,531
MYGNFirst Eagle Investment 2014-06-30 Sold Out -0.026%$33.1 - $42.21
($37.11)
$ 30.62-17%Sold Out0
MYGNThird Avenue Management 2014-03-31 Sold Out -0.13%$20.79 - $38.17
($30.6)
$ 30.620%Sold Out0
MYGNFirst Eagle Investment 2014-03-31 Buy 0.03%$20.79 - $38.17
($30.6)
$ 30.620%New holding284,826
MYGNRonald Muhlenkamp 2013-12-31 Sold Out -2.3%$20.79 - $30.65
($25.36)
$ 30.6221%Sold Out0
MYGNJoel Greenblatt 2013-12-31 Add0.18%$20.79 - $30.65
($25.36)
$ 30.6221%Add 36.27%1,316,314
MYGNThird Avenue Management 2013-12-31 Buy 0.13%$20.79 - $30.65
($25.36)
$ 30.6221%New holding328,314
MYGNJoel Greenblatt 2013-09-30 Add0.32%$24.396 - $31.8
($28.51)
$ 30.627%Add 74.78%965,987
MYGNRonald Muhlenkamp 2013-06-30 Buy 2.7%$24.35 - $34.26
($28.98)
$ 30.626%New holding481,900
MYGNRon Baron 2013-06-30 Sold Out -0.09%$24.35 - $34.26
($28.98)
$ 30.626%Sold Out0
MYGNJoel Greenblatt 2013-03-31 Add0.24%$24.19 - $27.68
($25.95)
$ 30.6218%Add 62.99%489,388
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

MYGN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


MYGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Ford AlexanderPresident, MGL 2016-06-21Sell18,637$30.87-0.81view
King Gary A.Exec. VP International Ops 2016-04-06Sell15,000$39.03-21.55view
King Gary A.Exec. VP International Ops 2016-04-01Sell15,000$38.12-19.67view
GILBERT WALTER PHDDirector 2015-12-11Sell5,000$42.23-27.49view
Phanstiel S. LouiseDirector 2015-12-08Sell5,000$44-30.41view
DREISMANN HEINRICHDirector 2015-11-05Sell60,000$44.44-31.1view
MARSH RICHARD ME.V.P., General Counsel 2015-11-04Sell35,000$44.5-31.19view
King Gary A.Exec. VP International Ops 2015-10-28Sell10,000$42.82-28.49view
LANCHBURY JERRY SChief Scientific Officer 2015-10-28Sell50,962$41.86-26.85view
LANCHBURY JERRY SChief Scientific Officer 2015-10-27Sell24,767$41.8-26.75view

Quarterly/Annual Reports about MYGN:

News about MYGN:

Articles On GuruFocus.com
Chuck Royce Reduces Several Positions in 4th Quarter Feb 05 2016 
Chuck Royce Comments on Myriad Genetics Oct 08 2014 
Chuck Royce’s Royce Premier Fund Second Quarter 2014 Manager Commentary Oct 08 2014 
Why I Bought Myriad Genetics (MYGN) Apr 28 2014 
Scott Black, Delphi Management Recommends Stocks Nov 19 2013 
Surfing for Billionaire Bargains Sep 22 2013 
Baron Funds Comments on Myriad Genetics Inc. Jun 06 2013 
RS Investments' Value Fund First Quarter 2012 Mutual Fund Commentary Apr 17 2012 
Chuck Royce Buys Hawkins Inc., Myriad Genetics, and Fairchild Semiconductor Jul 07 2011 
Myriad Genetics Inc. Reports Operating Results (10-Q) May 05 2010 

More From Other Websites
MYRIAD GENETICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jun 29 2016
Myriad's myChoice® HRD Test Successfully Identifies Patients that Meet Primary Endpoint in TESARO's... Jun 29 2016
Myriad’s myChoice® HRD Test Successfully Identifies Patients that Meet Primary Endpoint in... Jun 29 2016
7:15 am Myriad Genetics announces its myChoice HRD test successfully identified an increased number... Jun 29 2016
Crescendo Bioscience Announces that New Data on Vectra® DA Will Be Presented at the European League... Jun 10 2016
MYRIAD GENETICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 07 2016
Myriad Gets $200 Million More For Share Repurchase Program Jun 07 2016
Myraid Genetics increases share buyback program by $200 million Jun 07 2016
Myriad Board Approves $200 Million Increase in Share Repurchase Program Jun 07 2016
Myriad Board Approves $200 Million Increase in Share Repurchase Program Jun 07 2016
Myriad Genetics to Present at the 2016 Goldman Sachs Healthcare Conference Jun 06 2016
Myriad myRisk® Hereditary Cancer Test Demonstrates the Magnitude of Breast and Ovarian Cancer Risk... Jun 06 2016
Myriad Will Present Three New Hereditary Cancer Studies at the ASCO Annual Meeting Jun 05 2016
Myriad Will Present Three New Hereditary Cancer Studies at the ASCO Annual Meeting Jun 05 2016
Myriad Genetics Buys Sividon Diagnostics, Gains EndoPredict Jun 03 2016
Myriad Acquires Sividon Diagnostics May 31 2016
MYRIAD GENETICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits May 31 2016
Myriad Acquires Sividon Diagnostics May 31 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)